key: cord-0752707-elab64ln
authors: Wang, Feng-Sheng; Chen, Ke-Lin; Chu, Sz-Wei
title: Human/SARS-CoV-2 Genome-Scale Metabolic Modeling to Discover Potential Antiviral Targets for COVID-19
date: 2022-02-15
journal: J Taiwan Inst Chem Eng
DOI: 10.1016/j.jtice.2022.104273
sha: 8418a227c84f59e82a45b83e383a19dfb4a8bc80
doc_id: 752707
cord_uid: elab64ln

BACKGROUND: Coronavirus disease 2019 (COVID-19) has caused a substantial increase in mortality and economic and social disruption. The absence of US Food and Drug Administration–approved drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need for new therapeutic drugs to combat COVID-19. METHODS: The present study proposed a fuzzy hierarchical optimization framework for identifying potential antiviral targets for COVID-19. The objectives in the decision-making problem were not only to evaluate the elimination of the virus growth, but also to minimize side effects causing treatment. The identified candidate targets could promote processes of drug discovery and development. SIGNIFICANT FINDINGS: Our gene-centric method revealed that dihydroorotate dehydrogenase (DHODH) inhibition could reduce viral biomass growth and metabolic deviation by 99.4% and 65.6%, respectively, and increase cell viability by 70.4%. We also identified two-target combinations that could completely block viral biomass growth and more effectively prevent metabolic deviation. We also discovered that the inhibition of two antiviral metabolites, cytidine triphosphate (CTP) and uridine-5′-triphosphate (UTP), exhibits effects similar to those of molnupiravir, which is undergoing phase III clinical trials. Our predictions also indicate that CTP and UTP inhibition blocks viral RNA replication through a similar mechanism to that of molnupiravir.

The coronavirus disease 2019 (COVID- 19) pandemic was caused by the infectious spread of the novel new acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to as the genus -coronavirus [1] . COVID-19 has resulted in a substantial increase in mortality and severe economic and social disruption worldwide [2] . According to the World Health Organization (WHO)

COVID-19 dashboard [3] , as of January 27, 2022, COVID-19 had been responsible for over 5.6 million deaths in 194 countries and over 360 million infections. Facing this unprecedented crisis, many research groups, industries, and governments have expended considerable effort and resources to develop vaccines and medications to combat COVID-19 [4] . Several prevention methods and treatments for COVID-19, such as mask wearing, social distancing, and vaccination, have been promulgated by the Taiwan Centers for Disease Control and Prevention and similar agencies in nearly every country [5] . Vaccination can prevent viral infection and reduce the spread of the disease. Authorized COVID-19 vaccines are now widely available. According to the WHO dashboard (https://covid19.who.int/), as of January 25, 2022, a total of over 9.6 billion vaccine doses had been administered. However, the absence of US Food and Drug Administration (FDA)-approved drugs against SARS-CoV-2 highlights an urgent need to design new drugs [6] . Several approaches [6] [7] [8] [9] [10] [11] [12] to drug screening and repurposing have been developed to identify potential agents for treating COVID-19.

The rapid identification of potential therapeutic targets for COVID-19 is essential. Computational methods and systems biology approaches can play key roles in the discovery of suitable drugs. Constraint-based modeling (CBM) has been successfully applied in fundamental research [13] [14] [15] , the inference of oncogenes [16] [17] [18] [19] [20] [21] [22] , the discovery of anticancer targets [23] [24] [25] [26] in oncology, microbial engineering [27] [28] [29] , and other research fields. CBM uses data-and knowledge-driven constraints to identify feasible metabolic flux distributions for a given condition [13, 14] . The SARS-CoV-2 Alpha variant has been incorporated into the human alveolar macrophage model iAB-AMØ-1410 [30] [31] [32] , a genome-scale metabolic model (GSMM) of normal human bronchial epithelial cells [33] , a human metabolic reaction model [34] , and the human GSMM Recon 2.2 [35, 36] . These metabolic models of infection have been applied to computationally identify targets for combating thus, more than 30 million combinations must be analyzed to consider all two-target reactions through the numerical approach.

The present study integrated the SARS-CoV-2 Delta variant into the genome-scale human metabolic model Recon 3D [37] to present the viral infection.

We developed a fuzzy multiobjective hieratical optimization framework based on a modification of Identifying Anticancer Target (IACT) framework [38, 39] to mimic general wet-lab experiments and discover potential targets for treating COVID-19.

The objectives were to limit viral biomass growth, maximize cell viability, and minimize metabolic deviation of the cells perturbed by potential treatments. The optimization method was employed in the infection model to consider target combinations of not only genes but also metabolites. Fuzzy set theory was applied to convert the multiobjective optimization problem into a maximizing decision-making problem, which was a mixed-integer trilevel optimization problem. Currently available commercial software tools cannot solve the fuzzy hierarchical optimization problem. Conventional genetic algorithms can be extended to solve the problem to obtain global solutions [40] . This study applied the nested hybrid differential evolution (NHDE) to solve the decision-making problem [38, 39] to obtain optimal antiviral targets.

Viruses are nonliving entities and do not have their own metabolism for reproduction; therefore, they are entirely dependent on the hosts that they infect.

According to experimental studies, viral infection leads to significant metabolic alterations in the host, including increases in the glycolysis rate and changes in adenosine triphosphate (ATP) production [41] [42] [43] [44] . A key step in the viral replication is the synthesis of the viral biomass within the host cell, including structural proteins and genetic material. 

We developed a computer-aided strategy for screening potential therapeutic antiviral targets to combat COVID-19. The screening strategy was designed to identify not only antiviral enzymes, but also anti-metabolites. The antiviral target discovery (AVTD) framework described in Fig.1 was formulated as a hierarchical optimization problem based on a modified form of IACT framework [38, 39] to mimic a wet-lab experiment. The hierarchical screening procedure was formulated as a trilevel optimization problem consisting of an outer optimization problem with multiple objectives and subject to two loop inner optimization problems describing the characteristics of treated and perturbed cells. Fuzzy minimizing the biomass growth of treated cells and perturbed cells: 

The first objective is the fuzzy minimization of the viral biomass, i.e. the viral biomass production ( TR 

where Down-regulation :

Knockout :

where  IZ is the set of reactions regulated by isozymes determined using the gene-protein-reaction (GPR) associations, and modulation parameter  is determined by a nested hybrid differential evolution (NHDE) algorithm. The metabolite-centric regulators modulate the synthesis reactions of the active metabolites. The LBs and

UBs of modulated reactions for the i th active metabolite are restricted as

Regulated bounds for the active metabolite:

Up-regulation:

1 ; 0 and 1 ; 0 and Down-regulation : 

- Figure 2 . Illustrations of gene-and metabolite-centric approaches. (A) In the gene-centric approach, the reaction r 1 is catalyzed by isozymes, E 1 and E 2 , and the reaction r 2 is regulated by E 1 . The isozymes, E 1 and E 2 , are knocked out to inhibit r 1 , and r 2 is also blocked by E 1 . (B) In the metabolite-centric approach, the metabolite, M 1 , is inhibited, and the synthesis reactions, r 2 , r 3 and r 4 are thereby also inhibited.

The outer optimization problem in the AVTD framework comprises various fuzzy objective functions. Following procedures similar to those used by Wang et al. [38] , the fuzzy multiobjective hierarchical optimization problem was converted into a maximizing decision-making problem using fuzzy set theory. The maximization problem is expressed as follows.

subject to the inner optimization problems:

1. FBA and UFD problems for treating host-virus cells 2. FBA and UFD problems for perturbing host cells due to treatment

where  VBOF ,  CV and  MD are the membership grades of the VBOF, cell viability, and metabolic deviation, respectively, and w is a weighting factor. The transformation of each fuzzy objective function in the outer optimization problem describes as follows.

A one-side linear membership function is applied to convert each fuzzy minimization objective in Eq. (13) 

The second and third goals in the outer optimization problem are combined to determine the cell viability of the treated and perturbed cells through the computation of mean-min operation [ 

where  c is the set of species located in different compartments of the cell. 

Hence, overall metabolic deviation is defined as

With the intersection of the membership functions, the fuzzy multi-objectives can transformed into the hierarchical fitness  D by Eq.(17) for maximization. The optimality of the AVTD problem can be demonstrated using a procedure similar to that described by Wang et al. [38] . The maximizing decision-making problem (17) is a mixed-integer trilevel optimization problem involving linear and quadratic programming. It is a high dimension NP-hard problem that no commercial software has solved. In this study, we modified the primal version of NHDE algorithm to solve the maximizing decision-making problem (17) . The NHDE algorithm is a parallel direct search procedure and extended from the hybrid differential algorithm [47] . It has succeeded to solve the NP-hard problems such as strain design problems [29] , oncogene inference problems [18] [19] [20] [21] [22] and anticancer target design problems [38, 39] .

The performance and solution quality of the NHDE algorithm depended on three key setting factors: tolerance ratio used in migration, population size, and maximum number of iterations. The tolerance ratio was set to 0.05. A population size of 50 was used and the default number of iterations was 100.

We used the stoichiometric coefficients of the amino acids and nucleotides in the viral pseudo-reaction for Alpha and Delta variants, and the reaction of cell growth of the host cell to compare the stoichiometry between infected and uninfected cells.

Many of the amino acids and all of the nucleotides differed substantially in stoichiometry between the viral pseudo-reaction and biomass reaction of the host cells, as illustrated in Fig. 3A . The coefficients of glutamic acid (Glu), histidine (His) and

proline (Pro) for the infected cells decreased significantly. By contrast, the coefficients of tryptophan (Trp), asparagine (Asn) and tyrosine (Tyr) for the infected cells increased. The difference of stoichiometric coefficients for leucine (Leu), alanine (Ala) and glycine (Gly) were nonsignificant. The stoichiometric coefficients for the Delta variant and host cells are presented in Fig. 3B . The stoichiometric coefficients for Leu, Ala and Gly in both cells were higher than those of the amino acids and nucleotides (Fig. 3B) . The stoichiometric coefficients of RNA nucleotides were more than 2.6-fold higher (log2 fold change  1.38). The stoichiometric coefficients for ATP and UTP were greater than those for guanosine-5'-triphosphate (GTP) and

cytidine triphosphate (CTP), as illustrated in Fig. 3B .

RNA and protein sequencing of the SARS-CoV-2 Alpha variant was also applied to determine the stoichiometric coefficients for the VBOF for comparison. The stoichiometry of the Alpha variant was nearly identical to that of the Delta variant, as illustrated in Fig. 3A . To compare the protein sequences of the viruses, we first used the Expasy Translate tool (https://www.expasy.org/resources/translate) to translate the RNA sequences into the corresponding protein sequences, which were identical to the protein sequences accessed from the NCBI database [45] . We then compared the variants' sequence alignments, and identified few differences in structural and nonstructural proteins of these variations ( Table 1 ). The results indicated that the structural spike protein (S protein) of both viruses consists of 1273 amino acids and exhibit nine variations, and the nucleocapsid has three variations. The nonstructural protein ORF1ab was found to comprise 7096 amino acids and exhibit seven variations.

The altered locations of the proteins are listed in Table 1 . We discovered the sequences of the structural membrane (M) and envelop (E) proteins and nonstructural proteins ORF7B and ORF10 to be completely identical. 

The NHDE algorithm [38, 39] was applied to solve the maximizing decision problem in Eq. (17) by using the gene-centric approach defined in Eq. (15) to discover optimal enzyme targets. The algorithm was run several times to identify a set of single gene targets exhibiting the highest fitness among 2248 enzyme-encoding genes. The NHDE algorithm is a genetic algorithm that can obtain and rank targets by fitness. We identified five potential target enzymes with a membership grade for VBOF greater than 0.762, as listed in Table 2 . Two targets, dihydroorotate dehydrogenase (DHODH) and ribose-phosphate pyrophosphokinase 3 (PRPS1L1), participated in the metabolism on pyrimidine and purine, which are used for RNA and DNA synthesis.

3-hydroxyisobutyrate dehydrogenase (HIBADH) partially participates in the amino acid degradation related to protein synthesis. Aquaporin-9 (AQP9) and sodium/bile acid cotransporter (SLC10A1) participate in bile secretion. SARS-CoV-2 was recently discovered in the bile of a patient with severe COVID-19 [48, 49] . The membership grade ( VBOF ) for the VBOF reflects the percentage decrease in viral biomass production in treated cells. When  VBOF = 1, viral biomass production has completely stopped. On the basis of this computation, we determined that each of these single-target gene treatments could reduce viral biomass production by more than 76%. The enzyme DHODH catalyzes the oxidation of dihydroorotate (Dhor-S) to orotate (Orot) by using ubiquinone as an electron acceptor (Fig. 4) . Therefore, DHODH inhibitor may effectively combat COVID-19 while causing fewer side effect than other treatments cause ( Table 2) . Some studies have suggested that DHODH inhibitors can be used to treat autoimmune diseases [50] and cancers such as small-cell lung cancer [51] and acute myeloid leukemia [52] . Leflunomide is an approved DHODH inhibitor that widely used as a modest immune regulator to treat autoimmune diseases, in treating COVID-19 disease with a small-scale of patients [53] . An orally bioavailable compound, PTC299, is a potential anti-COVID-19

inhibitor of DHODH to reduce SARS-CoV-2 replication [54] . Based on the computational results, we observed DHODH to be a promising antiviral target for COVID-19; this result is consistent with previous reports [53] [54] [55] [56] [57] . The AVTD framework can be used to identify promising targets for treating COVID-19 and to decipher metabolic mechanisms of inhibition for treatment (Fig. 4) . We searched DrugBank [58] and identified 26 drugs that inhibit DHODH, 25 that inhibit SLC10A1, and 1 that inhibits HIBADH and AQP9. These are all potential candidates for drug repurposing to combat COVID-19. 

The viral pseudo-reaction in Eq. (1) used 20 amino acids and four nucleotides to produce viral biomass. Using the metabolite-centric approach, we first downregulated each one of these building metabolites to investigate the performance of each antimetabolite treatment, as illustrated in Fig. 6 [60, 61] . In this study, the inhibition of CTP and UTP exhibited effects similar to those of molnupiravir (Fig. 6) . The prodrug remdesivir acts as an adenosine nucleoside triphosphate analog to interfere with the action of viral RdRp [62] . Our computational predictions indicate that ATP inhibition would exert an effect similar to that of remdesivir by blocking viral RNA replication but result in low cell viability and high metabolic alteration. We performed a series of computations to obtain a set of two-target combinations and their corresponding optimal grades (Fig.   7 ), and we compared the two-target combinations with their single-target counterparts On the basis of the aforementioned computations, the building blocks of viral biomass-amino acids and nucleotides-were eliminated to diminish viral growth. In addition, we identified seven single antimetabolite targets that could nearly block viral biomass growth (Fig. 8 ) while achieving membership grades of cell viability and metabolic deviation greater than 0.67. These anti-metabolites related to metabolites in metabolic pathways regulated by DHODH are nucleotide derivatives that participate in the pyrimidine biosynthetic pathway to produce cytosine, thymine, and uracil for viral RNA replication, as illustrated in Fig. 4 . Using these data, we identified various two-target antimetabolite combinations that obtained higher VBOF, cell vitality, and metabolic deviation grades than their single-target counterparts (Fig. 8) . 

Authorized COVID-19 vaccines are now widely available. However, the absence of FDA-approved drugs against SARS-CoV-2 has highlighted an urgent need to manufacture and screen new drugs or repurpose existing drugs and identify promising targets for treating COVID-19. This study developed the AVTD optimization framework to mimic a wet-lab experiment for discovering antiviral gene and metabolite targets against COVID-19. The basic step in drug discovery and development processes is to discover potential antiviral targets. The identified antiviral enzymes and metabolites through AVTD framework can provide for biologists to carry on subsequent progressing in order to save a lot of times for screening procedures.

The gene and protein sequences of the SARS-CoV-2 Alpha and Delta variants were used to model the viral biomass growth reaction. Comparison of the protein sequences of the Alpha and Delta variants revealed few differences in their structural and nonstructural proteins, and the stoichiometries of the variants were nearly identical. We generated an integrated HV human GSMM using Recon3D and the viral stoichiometry. The AVTD framework employs a fuzzy hierarchical optimization method, which we used to identify potential antiviral targets using the integrated model. Potential treatments were evaluated in terms of their ability to limit viral biomass growth and metabolic deviation while maximizing cell viability in both treated and perturbed cells.

The AVTD framework identified not only gene regulator targets but also metabolite-centric targets. DHODH inhibitors reduced viral biomass growth by 99.4%

and achieved cell viability and metabolic deviation grades of 70.4% and 65.6%, respectively. Consistent with our predictions, several articles have recently reported that DHODH inhibitors can potentially be used to treat COVID-19. We also identified two-target combinations that could completely block viral biomass growth while achieving even higher metabolic deviation grades. Some of the identified targets are modulated by drugs existing in the DrugBank database, as listed in Additional File 1.

These drugs may serve as potential candidates for repurposing to develop new treatments for COVID-19.

Through a metabolite-centric approach, we identified 19 amino acids and four nucleotides that could nearly terminate viral biomass growth (except His) and achieve satisfactory membership grades for cell viability (except ATP). The inhibition of CTP and UTP exhibited effects similar to those of molnupiravir, which is undergoing phase III clinical trials for COVID-19 treatment. In addition, we determined that certain two-target combinations of antiviral enzymes and metabolites could achieve similar antiviral results with higher grades for cell viability and metabolic deviation.

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options

An interactive web-based dashboard to track COVID-19 in real time

How chemical engineers can contribute to fight the COVID-19

Analysis of COVID-19 prevention and treatment in Taiwan

Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy

Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease. International journal of peptide research and therapeutics

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach

Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures

Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2. Available at SSRN 3678908

What is flux balance analysis? Nature biotechnology

Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v. 3.0. Nature protocols

Challenges of cultivated meat production and applications of genome-scale metabolic modeling

Modeling cancer metabolism on a genome scale. Molecular systems biology

Genome scale metabolic modeling of cancer

Genome-scale metabolic modeling with protein expressions of normal and cancerous colorectal tissues for oncogene inference

Oncogene inference optimization using constraint-based modelling incorporated with protein expression in normal and tumour tissues

Optimization of a modeling platform to predict oncogenes from genome-scale metabolic networks of nonsmall-cell lung cancers. FEBS Open Bio

Inferring oncoenzymes in a genome-scale metabolic network for hepatocytes using bilevel optimization framework

Flux balance analysis predicts Warburg-like effects of mouse hepatocyte deficient in miR-122a

Human systems biology and metabolic modelling: a review-from disease metabolism to precision medicine

Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Molecular systems biology

Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling

An integrated computational and experimental study uncovers FUT 9 as a metabolic driver of colorectal cancer. Molecular systems biology

Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization

EMILiO: a fast algorithm for genome-scale strain design. Metabolic engineering

Optimal design of growth-coupled production strains using nested hybrid differential evolution

FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2

Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target

Repositioning of Drugs and Drug Combinations for SARS-CoV-2 Infected Lung through Constraint-Based Modelling

Genome Scale-Differential Flux Analysis reveals deregulation of lung cell metabolism on SARS-CoV-2 infection

A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19

Inhibiting the reproduction of SARS-CoV-2 through perturbations in human lung cell metabolic network

Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19

Recon3D enables a three-dimensional view of gene variation in human metabolism

Fuzzy multiobjective hierarchical optimization with application to identify antienzymes of colon cancer cells

Computer-Aided Design for Identifying Anticancer Targets in Genome-Scale Metabolic Models of Colon Cancer

Simulation and optimization of a continuous biochemical reactor

Viral activation of cellular metabolism

SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition

Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection

Integrated human-virus metabolic stoichiometric modelling predicts host-based antiviral targets against

Dengue and Zika viruses

.617. 2 Delta variant emergence and vaccine breakthrough

Fuzzy sets and interactive multiobjective optimization: Springer science & business media

Hybrid method of evolutionary algorithms for static and dynamic optimization problems with application to a fed-batch fermentation process

Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics

SARS-CoV-2 was found in the bile juice from a patient with severe COVID-19

Use of dihydroorotate dehydrogenase inhibitors for treatment of autoimmune diseases and cancer

Identification of DHODH as a therapeutic target in small cell lung cancer. Science translational medicine

The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors -Leflunomide‖ and -Teriflunomide‖ in Covid-19: A narrative review

The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines

Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2

Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection

A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors

DrugBank 5.0: a major update to the DrugBank database

Network-based prediction of drug combinations

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv

Remdesivir for the treatment of Covid-19

The financial support from Ministry of Science and Technology of Taiwan (Grant MOST110-2320-B-194-005) is highly appreciated.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.